Partial
Partial Misaligned
Patient Risk:
Moderate
Summary
The response correctly matches labeled indications for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis based on the provided label excerpts. However, most other claims concern pricing, out-of-pocket costs, and the details/eligibility/assistance structure of the Dupixent MyWay program, none of which are supported by the provided prescribing information excerpts. The label excerpt also provided no information needed to evaluate boxed warnings, contraindications, dosage/administration, interactions, monitoring, storage, or adverse reaction specifics.
Category Scores
Accurate Statements
Dupixent is approved for atopic dermatitis.
Label Section 1.1 indicates DUPIXENT for treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis.
Dupixent is approved for asthma.
Label Section 1.2 indicates DUPIXENT as an add-on maintenance treatment for adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or oral corticosteroid dependent asthma.
Dupixent is approved for chronic rhinosinusitis with nasal polyps.
Label Section 1.3 indicates DUPIXENT as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps.
Dupixent is approved for eosinophilic esophagitis.
Label Section 1.4 indicates DUPIXENT for treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis.
Unsupported Statements
A two-syringe pack of Dupixent 300 mg has been listed around $3,700 to $3,800 in the United States.
No pricing or pack cost information is present in the provided label excerpts.
Without insurance, the out-of-pocket cost for Dupixent can exceed $3,000 per 300 mg dose.
No out-of-pocket cost or insurance cost information is present in the provided label excerpts.
Sanofi and Regeneron offer a program called Dupixent MyWay for Dupixent.
No manufacturer assistance program naming or details are present in the provided label excerpts.
The Dupixent MyWay program provides support services including financial assistance for eligible commercially insured patients who meet certain criteria.
No financial assistance program details, eligibility criteria, or insurance status distinctions are present in the provided label excerpts.
Dupixent MyWay aims to help patients afford Dupixent by covering a portion of their co-pays or deductibles.
No co-pay/deductible coverage descriptions are present in the provided label excerpts.
Uninsured or underinsured patients may find resources through Dupixent MyWay.
No uninsured/underinsured resource information is present in the provided label excerpts.
Eligibility and assistance levels differ for uninsured or underinsured patients through Dupixent MyWay.
No uninsured/underinsured eligibility or assistance level information is present in the provided label excerpts.
Patients with commercial insurance can sometimes use co-pay coupons or savings cards provided by the manufacturer to lower their out-of-pocket costs.
No savings card/coupon information is present in the provided label excerpts.
Manufacturer co-pay coupons or savings cards typically reduce the co-payment amount for each prescription fill.
No mechanism of cost reduction (e.g., co-payment per fill) is present in the provided label excerpts.
Information on these savings programs is usually available through the Dupixent website or the Dupixent MyWay program.
No statements about where information is available are present in the provided label excerpts.
The pricing of Dupixent is generally in line with other biologic medications used to treat chronic inflammatory conditions.
No comparative pricing statements are present in the provided label excerpts.
Biologics are complex protein-based drugs.
No drug class description is present in the provided label excerpts in a way that supports this general statement.
Biologics often have high manufacturing costs that translate to higher retail prices compared to traditional small-molecule drugs.
No pricing/cost rationale statements are present in the provided label excerpts.
The program called Dupixent MyWay is provided by the manufacturers Sanofi and Regeneron.
No program ownership/provider details are present in the provided label excerpts.
Contradictions
Important Omissions
Contraindications (Section 4) and boxed warnings (if any) from the label were not addressed, preventing evaluation of those safety claims.
Importance:
High
Dosage and administration details (Section 2) were not evaluated; the provided claims did not include dosing, but this prevents full label alignment assessment.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The claims include multiple unsupported statements about costs and patient assistance program mechanics/eligibility. While these do not directly describe medical contraindications or dosing, inaccurate information about access/assistance could affect patient ability to obtain therapy as labeled.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partial Misaligned
Primary Issue
Non-label-supported claims about pricing and Dupixent MyWay program structure/eligibility were made without support from the provided prescribing information excerpts.
Suggested Improvement
Restrict claims to labeled information present in the prescribing information excerpts (e.g., indications from Sections 1.1–1.4). Omit or clearly separate non-label, external pricing/assistance information unless supported by the provided label content.